The group's product Semaglutide Injection marketing registration application been accepted
Filed with HKEX · Stock code 3933 · · 2 pages · English
Summary by 6ix AI
United Laboratories International Holdings Ltd. announced that its marketing registration application for Semaglutide Injection has been accepted by the China National Medical Products Administration. The acceptance of this application broadens the product's indication portfolio and aims to benefit a wider patient population. The company plans to continue investing in research and development to enhance its competitiveness in the biopharmaceutical sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
United Laboratories International Holdings Ltd. on 6ix
Earlier from United Laboratories International
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Second milestone payment from novo for exclusive license agreement of UBT251
- Notification Letter to Non-register Holder and Reply Form
- Notification Letter to Shareholder and Reply Form
- 2026 Interim report
Later from United Laboratories International
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
- Voluntary announcement vesting of award shares
Follow United Laboratories International into a list and get an email when it puts out news.
Follow United Laboratories International